In a histology-independent trial of the BRAF inhibitor vemurafenib, a cohort of patients with non-squamous cell lung carcinoma harboring the BRAF V600E mutation demonstrated a 42% partial response rate after treatment with vemurafenib (13). Here, BRAF is linked to squamous cell lung carcinoma.